Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, shared a post on LinkedIn:
“MET-driven NSCLC accounts for less than 5% of lung cancer cases, yet it remains one of the most important molecular subtypes in thoracic oncology.
Why?
Because this disease is biologically aggressive, strongly linked to brain metastases, and MET amplification is a major mechanism of resistance in EGFR-mutated NSCLC.
This explains the rapid expansion of MET-targeted therapies and combination strategies despite the relatively small patient population.
Precision oncology is not about numbers of patients – it is about the clinical impact on the patients who need it most.
I created this infographic to highlight the biology, treatment landscape, and growing importance of MET-driven NSCLC.”
Other articles featuring Rasha Aboelhassan on OncoDaily.